274 related articles for article (PubMed ID: 29137492)
1. A Guide to Topical Vehicle Formulations.
Mayba JN; Gooderham MJ
J Cutan Med Surg; 2018; 22(2):207-212. PubMed ID: 29137492
[TBL] [Abstract][Full Text] [Related]
2. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis.
Eastman WJ; Malahias S; Delconte J; DiBenedetti D
Cutis; 2014 Jul; 94(1):46-53. PubMed ID: 25101344
[TBL] [Abstract][Full Text] [Related]
3. Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance.
Jackson JM; Pelle M
J Drugs Dermatol; 2011 Jun; 10(6):627-33. PubMed ID: 21637903
[TBL] [Abstract][Full Text] [Related]
4. Increasing use of non-traditional vehicles for psoriasis and other inflammatory skin conditions.
Huang KE; Davis SA; Cantrell J; Feldman SR
Dermatol Online J; 2014 Sep; 20(9):. PubMed ID: 25244174
[TBL] [Abstract][Full Text] [Related]
5. [Corticosteroids and their vehicle in the treatment of scalp psoriasis].
Wauters O; Roland I; De la Brassinne M
Rev Med Liege; 2007 Apr; 62(4):196-9. PubMed ID: 17566388
[TBL] [Abstract][Full Text] [Related]
6. [Non adherence and topical steroids].
Aubert H; Barbarot S
Ann Dermatol Venereol; 2012 Jan; 139 Suppl 1():S7-12. PubMed ID: 22305285
[TBL] [Abstract][Full Text] [Related]
7. Topical dermatological drug delivery: quo vadis?
Akomeah FK
Curr Drug Deliv; 2010 Oct; 7(4):283-96. PubMed ID: 20695839
[TBL] [Abstract][Full Text] [Related]
8. Non-adherence and measures to improve adherence in the topical treatment of psoriasis.
Zschocke I; Mrowietz U; Karakasili E; Reich K
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():4-9. PubMed ID: 24684738
[TBL] [Abstract][Full Text] [Related]
9. Topical drug delivery systems in dermatology: a review of patient adherence issues.
Tan X; Feldman SR; Chang J; Balkrishnan R
Expert Opin Drug Deliv; 2012 Oct; 9(10):1263-71. PubMed ID: 22861153
[TBL] [Abstract][Full Text] [Related]
10. Importance of vehicles in acne therapy.
Kircik LH
J Drugs Dermatol; 2011 Jun; 10(6):s17-23. PubMed ID: 21780342
[TBL] [Abstract][Full Text] [Related]
11. Patients with psoriasis prefer solution and foam vehicles: a quantitative assessment of vehicle preference.
Housman TS; Mellen BG; Rapp SR; Fleischer AB; Feldman SR
Cutis; 2002 Dec; 70(6):327-32. PubMed ID: 12502121
[TBL] [Abstract][Full Text] [Related]
12. Are ointments better than other vehicles for corticosteroid treatment of psoriasis?
Zivkovich AH; Feldman SR
J Drugs Dermatol; 2009 Jun; 8(6):570-2. PubMed ID: 19537382
[TBL] [Abstract][Full Text] [Related]
13. Novel topical drug delivery systems and their potential use in acne vulgaris.
Taglietti M; Hawkins CN; Rao J
Skin Therapy Lett; 2008 Jun; 13(5):6-8. PubMed ID: 18648713
[TBL] [Abstract][Full Text] [Related]
14. Adherence and patient satisfaction with topical treatment in psoriasis, and the use, and organoleptic properties of such treatments: a Delphi study with an expert panel and members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
Puig L; Carrascosa JM; Belinchón I; Fernández-Redondo V; Carretero G; Ruiz-Carrascosa JC; Careaga JM; de la Cueva P; Gárate MT; Ribera M; ;
Actas Dermosifiliogr; 2013; 104(6):488-96. PubMed ID: 23395400
[TBL] [Abstract][Full Text] [Related]
15. Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Stein Gold LF
Semin Cutan Med Surg; 2016 Mar; 35(2 Suppl 2):S36-44; quiz S45. PubMed ID: 27074696
[TBL] [Abstract][Full Text] [Related]
16. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
17. Expert recommendations: the use of the fixed combination calcipotriol and betamethasone dipropionate gel for the topical treatment of psoriasis.
Daudén E; Bewley A; Lambert J; Girolomoni G; Cambazard F; Reich K
J Eur Acad Dermatol Venereol; 2014 May; 28 Suppl 2():22-32. PubMed ID: 24684740
[TBL] [Abstract][Full Text] [Related]
18. Topical Desoximetasone 0.25% Spray and Its Vehicle Have Little Potential for Irritation or Sensitization.
Nadkarni A; Saleem MD; Feldman SR
J Drugs Dermatol; 2017 Aug; 16(8):755-758. PubMed ID: 28809990
[TBL] [Abstract][Full Text] [Related]
19. Pharmionics in dermatology: a review of topical medication adherence.
Lee IA; Maibach HI
Am J Clin Dermatol; 2006; 7(4):231-6. PubMed ID: 16901183
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Relevance and Therapeutic Benefit of Established Active Ingredients Incorporated into Advanced Foam Vehicles: Vehicle Characteristics Can Influence and Improve Patient Outcomes.
Del Rosso JQ; Kircik LH; Zeichner J; Stein Gold L
J Drugs Dermatol; 2019 Feb; 18(2s):s100-s107. PubMed ID: 30811153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
